TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15610655
Drug: Lower-radiation doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-radiation doses and smaller radiation field sizes
Study: 15610655
Drug: More intense
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intense drug combinations for high-risk patients
Study: 2044968
Drug: CAI treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAI treatments (MK-927 and MK-417)
Study: 26749217
Drug: Buprenorphine 3
Normalized name: buprenorphine 356 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 3 mg with naltrexone (50 mg initiated 12 hours before and given every 12 hours for 4 doses)
Study: 26749217
Drug: Open-label moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label moxifloxacin 400 mg with placebo naltrexone
Study: 20813792
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (exact dosage not specified)
Study: 15890561
Drug: Sitaxsentan (SITAX)
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan (SITAX) 100 mg orally once daily
Study: 15890561
Drug: Sitaxsentan (SITAX)
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan (SITAX) 300 mg orally once daily
Study: 9831969
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg loading dose of gentamicin or tobramycin (study group, n=4)
Study: 9831969
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing regimen of 2 mg/kg loading dose followed by maintenance dose (control group, n=7)
Study: 2530716
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccination
Study: 2530716
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis B vaccination
Study: 21993710
Drug: Olmesartan (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (10-40 mg once daily)
Study: 19624387
Drug: Quetiapine, 300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine, 300-600 mg/day
Study: 9706913
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 2 g
Study: 14741082
Drug: Aprotinin (AP)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (AP) high-dose according to Hammersmith
Study: 3326574
Drug: Diary card
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diary card evaluation during PEP mask therapy
Study: 22695489
Drug: Almorexant 1000
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 1000 mg
Study: 18798500
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 1.6 mg hypodermic injection, administered for 10 times
Study: 8885956
Drug: t.i.d. dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. dosing
Study: 8885956
Drug: b.i.d. dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. dosing
Study: 8885956
Drug: t.i.d. and
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. and titration conditions
Study: 2063702
Drug: Household composition
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household composition and control over food selection/preparation
Study: 2063702
Drug: Attendance at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attendance at treatment sessions
Study: 6391932
Drug: diflunisal 1000
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diflunisal 1000 mg daily
Study: 6391932
Drug: naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 750 mg daily
Study: 30486711
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (guideline-directed therapy for HF)
Study: 12077088
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (2 mg/kg intravenously three times a week for two weeks)
Study: 12077088
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (2 mg/kg intravenously three times a week for four weeks)
Study: 28237428
Drug: Adjunct slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct slow-release dexamethasone implant (Ozurdex; 0.7 mg)
Study: 28237428
Drug: Adjunct slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct slow-release dexamethasone implant (Ozurdex)
Study: 19414940
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg after each dialysis session for six months
Study: 16519421
Drug: Pharmacological testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological testing (phentolamine, lidocaine, ketamine, thiopental, morphine, placebo)
Study: 7848901
Drug: Guggulipid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guggulipid (50 mg capsules twice daily for 24 weeks)
Study: 7848901
Drug: Placebo (capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsules twice daily for 24 weeks)
Study: 2903480
Drug: Surfactant (Curosurf)
Normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (Curosurf) 200 mg/kg
Study: 4513355
Drug: Intermittent combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent combination chemotherapy as the only form of maintenance
Study: 4513355
Drug: Weekly immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly immunotherapy in addition to chemotherapy
Study: 12144580
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg
Study: 26365443
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of PTQXT
Study: 26365443
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of PTQXT combined with external application of Chinese herbs
Study: 26365443
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral antihistamine and placebo PTQXT pills with topical 1% mometasone furoate)
Study: 26365443
Drug: Both Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Chinese herbal medicine-treated groups
Study: 22289539
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg/kg intravenous bolus plus normal saline by intravenous infusion (K group, n = 30)
Study: 22289539
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg/kg intravenous bolus plus remifentanil 0.15 μg/kg per min intravenous infusion (KR group, n = 30)
Study: 19491658
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP (8‐10 h/week, maximum 50 microg/kg/min) for 8 weeks
Study: 16941969
Drug: Oral anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-inflammatory analgesic medicine combined with acupuncture at Tiaokou (ST 38)
Study: 16941969
Drug: Oral anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-inflammatory analgesic medicine
Study: 12694150
Drug: Sufentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.3 micro g kg‐1
Study: 10731509
Drug: High-calcium mineral
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium mineral water (344 mg Ca/L)
Study: 10731509
Drug: Low-calcium mineral
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium mineral water (<10 mg/L)
Study: 9163027
Drug: Aciclovir (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir (treatment of choice for HSE)
Study: 27372434
Drug: Lidocaine pre-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine pre-administration (1% lidocaine 30mg)
Study: 20653641
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg daily for 3 days
Study: 11236120
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose systemic methotrexate (50 mg/m2)
Study: 31593081
Drug: Multicomponent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent therapy (MT group) consisting of health education, exercise, and cognitive-behavioral therapy during 12 weeks in 2-hourly weekly sessions.
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 234 mg on Day 1
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 156 mg on Day 8
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 234 mg (Days 1 to 7)
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 156 mg (Days 8 to 36)
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 39 mg (Days 8 to 36)
Study: 21569242
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 234 mg (Days 8 to 36)
Study: 19355800
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg once daily
Study: 19355800
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg once daily
Study: 16573577
Drug: Alcohol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol plus energy drink (vodka 37.5% v/v and Red Bull 3.57 mL/kg)
Study: 12771499
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) with glass-ionomer
Study: 9179367
Drug: Viscum album
Normalized name: Viscum album
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscum album agglutinin-I (10 and 1 ng/ml)
Study: 9179367
Drug: Viscum album
Normalized name: Viscum album
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscum album agglutinin-I (lectin-enriched preparation)
Study: 26501386
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intraoperative methylprednisolone
Study: 20929999
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for 4 weeks
Study: 16871570
Drug: TMA Assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMA Assay (LOD 9.6 IU/mL)
Study: 12759295
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg, subcutaneously, twice weekly)
Study: 11120531
Drug: Methotrexate infusion
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate infusion therapy (100 mg/m² intravenous bolus followed by 200 mg/m² infusion)
Study: 11120531
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate, etoposide, and bleomycin)
Study: 8211872
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1.5 mg per day
Study: 8211872
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 1.5 mg per day
Study: 3102372
Drug: L-carnitine (4g/day)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (4g/day)
Study: 3102372
Drug: L-carnitine (2g/day)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (2g/day)
Study: 3102372
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-carnitine)
Study: 30975570
Drug: PHiD‐CV/dPly/PhtD (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV/dPly/PhtD (10 or 30 µg of each protein) with 3+0 schedule (2‐3‐4 months)
Study: 30975570
Drug: PHiD‐CV/dPly/PhtD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV/dPly/PhtD (30 µg of each protein) with 2+1 schedule (2‐4‐9 months)
Study: 30975570
Drug: DTPw‐HBV/Hib, OPV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw‐HBV/Hib, OPV, measles, yellow fever vaccines co-administered with pneumococcal proteins
Study: 30975570
Drug: Co-administered vaccines
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered vaccines
Study: 26649812
Drug: Focused Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused Enhanced Cognitive Behavior Therapy (CBT‐Ef)
Study: 26649812
Drug: Broad Enhanced
Normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad Enhanced Cognitive Behavior Therapy (CBT‐Eb)
Study: 16151286
Drug: Single-shot fascia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and saline for infusion
Study: 16151286
Drug: Continuous fascia
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and infusion
Study: 16151286
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with saline for both bolus and infusion
Study: 10533689
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam administration
Study: 10533689
Drug: Teaching at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching at 3 hours after midazolam administration
Study: 9084546
Drug: Midazolam (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.06 mg/kg) and Propofol (20 mg/5 s) for induction; Propofol (8 mg/kg/hr) for maintenance
Study: 9084546
Drug: Propofol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20 mg/5 s) for induction; Propofol (10 mg/kg/h) for maintenance
Study: 17136042
Drug: cholesterol-reducing diet
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholesterol-reducing diet (high in plant sterols 1.0 g/1000 kcal, soy protein 22.5 g/1000 kcal, viscous fibers 10 g/1000 kcal, almonds 23 g/1000 kcal)
Study: 7706804
Drug: Cidofovir alone
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir alone at doses of 0.5, 1.0, 3.0, or 10.0 mg/kg/week (20 patients)
Study: 7706804
Drug: Cidofovir at
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir at 3.0, 5.0, or 7.5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)
Study: 27876342
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg/d for 12 weeks
Study: 27876342
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids 1800 mg/d for 12 weeks
Study: 17694045
Drug: Discontinued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued warfarin (group 1)
Study: 17694045
Drug: Suturing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suturing and discontinued warfarin (group 3)
Study: 17694045
Drug: Continued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued warfarin (group 2)
Study: 17694045
Drug: Suturing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suturing and continued warfarin (group 4)
Study: 30077809
Drug: Symbicort® pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) with AeroChamber Plus® Flow‐Vu® spacer
Study: 30077809
Drug: Symbicort® pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) without spacer
Study: 22451195
Drug: FOLFOX/FOLFIRI sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX/FOLFIRI sequential chemotherapy
Study: 19035721
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine (5-15 mg/hour)
Study: 10713577
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors (ChIs)
Study: 9239913
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate and 2.5 mg medroxyprogesterone acetate
Study: 30291370
Drug: Topical atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical atorvastatin 1%
Study: 27617502
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (27 mg per day for 8 weeks)
Study: 27617502
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (320 mg per day for 8 weeks)
Study: 27617502
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 8 weeks)
Study: 19147689
Drug: Concomitant anthracycline
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant anthracycline therapy
Study: 16332430
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) as an add-on treatment
Study: 10365896
Drug: TUBT (tablet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUBT (tablet-based 13C urea breath test)
Study: 7578166
Drug: simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 10 mg daily
Study: 2194314
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg twice daily
Study: 7578166
Drug: cholestyramine 4
Normalized name: CHOLESTYRAMINE 4GM CHEW BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholestyramine 4 gm twice daily
Study: 2272022
Drug: Apomorphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (10 micrograms/kg subcutaneously with oral domperidone 10 mg)
Study: 2272022
Drug: Oral sultopride
Normalized name: Sultopride
DrugBank: Sultopride (DB13273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sultopride (50 mg)
Study: 23972505
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% nitroglycerin ointment
Study: 22357861
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and mask stimuli with distinct temporal frequencies; specific details on dosage and duration not applicable.
Study: 22357861
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and mask stimuli with equal contrast; specific details on dosage and duration not applicable.
Study: 22357861
Drug: Divisive gain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divisive gain control models with 30 ms integration time; specific details on dosage and duration not applicable.
Study: 22357861
Drug: Contrast normalization;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast normalization; specific details on dosage and duration not applicable.
Study: 18060342
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no infliximab therapy)
Study: 10624430
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (g. cyclopentolate 1% stat. and oc. chloramphenicol q.d.s. for 5 days)
Study: 10624430
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen followed by additional nightly ointment (Lacrilube) for 2 months
Study: 2188826
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg daily (n = 68)
Study: 2188826
Drug: Sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nifedipine 20 mg twice daily (n = 68)
Study: 7198465
Drug: plafibride (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: plafibride (1200 mg/d for 15 days)
Study: 25907488
Drug: Xinkeshu (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinkeshu (12 capsules/d) on top of standard therapy
Study: 25907488
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on top of standard therapy
Study: 21836413
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with half-dose verteporfin
Study: 19169191
Drug: Pharmacotherapy (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (e.g., selective serotonin reuptake inhibitors)
Study: 19169191
Drug: Consensus guidelines
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consensus guidelines on pharmacotherapy for PTSD